Introduction
Treatment of infectious diseases still remains an important and challenging problem because of a combination factors including newly emerging infectious diseases and increasing number of multi-drug resistant microbial pathogens with particular relevance for Gram-positive bacteria [1] [2] [3] [4] [5] . In spite of the large number of antibiotics and chemotherapeutics available for medical use, the emergence new antibiotic resistant bacterial strains in the last decades constitutes a substantial need for new class of antibacterial agents [6] .
During recent years, there have been intense investigations on thiadiazole and imidazo [2,1-b] [1, 3, 4] thiadiazole compounds, many of which are known to possess interesting pharmacological properties such as anticancer [7] , antitubercular [8] , antibacterial [9] , antifungal [10] , antimicrobial and anti-inflammatory [11, 12] , analgesic and antimicrobial [13] , anticonvulsant, analgesic [14] , and antisecretory [15] activities. Moreover, much interest has also been focused on the cardiotonic [16] , diuretic [17] and herbicidal [18] activities displayed by compounds incorporating this heterocyclic system.
The varied biological activities of rhodanines (2-thioxothiazolidin-4-one) and their analogues have been known from the beginning of the 20 th century. Rhodanines and 2,4-thiazolidinedione have become a pharmacologically important class of heterocyclic compounds since the introduction of various glitazones and epalrestat in to clinical use for treatment of type II diabetes and diabetic complications, respectively [19, 20] . Chemical modification of these heterocycles has constantly resulted in compounds with broad spectrum of pharmacological activities.
2,4-Thiazolidinedione derivatives constitute an important class of heterocyclic compounds for which diverse biological properties such as antibacterial and antifungal [21] [22] [23] [24] , antidiabetic [25] , cardiotonic [26] , anti-oedematus and analgesic [27] , cyclooxygenase and lipoxygenase inhibitory [28] activities have been documented along past decades.
In view of the high degree of bioactivity shown by the above two heterocyclic system, and initialization of our search for biological active heterocyclic compounds, it was envisaged to construct a system, which combines both these systems in a single molecular frame and to explore the additive effects towards their biological activities. Hence we are reporting herein the synthesis of imidazo [2,1-b] [1, 3, 4] thiadiazole derivatives and evaluation of their antibacterial and antifungal activities.
Experimental

Instrumentation
Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. Melting points were recorded on electrothermal melting point apparatus and are uncorrected. Thin layer chromatography (TLC) controls were carried out on precoated silica gel plates (F254 Merck). The IR spectra were recorded on Nicolet Impact 410 FT-IR spectrophotometer using KBr pellets. 1 H and 13 C NMR spectra were recorded on AMX-400, Bruker-400 liquidstate NMR spectrometer using tetramethylsilane (TMS) as the internal standard. Chemical shifts were recorded as  (ppm). Elemental analyses were carried out using a Perkin Elmer 2400-CHN Analyzer. Spectra facilities and elemental analysis were carried out by Sophisticated Analytical Instruments Facility (SAIF) division, Indian Institute of Science, Bangalore, India.
Synthesis
Synthesis of 2-amino-5-(3,4,5-trimethoxyphenyl)-1,3,4-thiadiazole (3)
2-amino-5-(3,4,5-trimethoxyphenyl)-1,3,4-thiadiazole was obtained according to the procedure described by Al-Omar et al. [29] and Mazzone et al. [30] with a modification. A mixture of equimolar quantities of 3,4,5-trimethoxy benzoic acid (0.1 mol), thiosemicarbazide (0.1 mol) and phosphorus oxychloride (30 mL) was refluxed gently for half an hour. After cooling, water was added (90 mL) and the mixture was refluxed for 4 h and filtered. The solution was neutralized by saturated solution of potassium hydroxide. [1, 3, 4] thiadiazole (4a-g) (0.01 mol) was added to the reagent and stirred at 0 °C for 30 min. The mixture was further stirred for 2h at room temperature and at 60 °C for additional 2 h. the reaction mixture was then poured in sodium carbonate solution and stirred at 90 °C for 2 h. After cooling, the mixture was diluted with water, extracted with chloroform, and collective extract was washed with water and dried over anhydrous sodium sulphate. The residue obtained after the removal of chloroform was recrystallized from suitable solvent to get the crystalline solid. [2,1-b] [1, 3, 4] 
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Microbiology
For the antibacterial and antifungal activity, the compounds were dissolved in dimethylsulfoxide (DMSO). Further dilutions of the compounds and standard drugs in the test medium were prepared at the required quantities of 128, 64, 32, 16, 8, 4, 2, 1 µg/mL concentrations with Mueller-Hinton broth and Sabouraud dextrose broth. The minimum inhibitory concentrations (MIC) were determined using the twofold serial dilution technique [32] . A control test was also performed containing inoculated broth supplemented with only DMSO at the same dilutions used in our experiments and found inactive in the culture medium. All the compounds were tested for their in vitro growth inhibitory activity against different bacteria and fungi, Ampicillin and Kanamycin were used as the reference standard for antibacterial activity while ketoconazole was used as the reference standard for antifungal activity, the MIC value were summarized in Table 1 .
The cultures were obtained from Mueller-Hinton broth for all the bacterial strains after 24 h of incubation at 37 ± 1 °C. Fungi were maintained in Sabouraud dextrose broth after incubation for 24 h at 25 ± 1 °C. Testing was carried out in Mueller-Hinton broth and Sabouraud dextrose broth at pH 7.4 and the twofold serial dilution technique was applied. The final inoculum's size was 10 5 CFU/mL for the antibacterial assay and 10 4 CFU/mL for the antifungal assay. A set of tubes containing only inoculated broth was used as controls. For the antibacterial assay after incubation for 24 h at 37±1 °C and after incubation for 48 h at 25 ± 1°C for antifungal assay, the tube with no growth of microorganism was recorded to represent the MIC expressed in µg/mL. Every experiment in the antibacterial and antifungal assays was replicated twice.
Results and discussion
Synthesis
The synthetic route of the compounds (6a-g and 7a-g) is outlined in Scheme 1. The 2-(2,4-dioxothiazolidin-3-yl)acetic acid (1) was prepared according to earlier reported method [31] and 2-(4-oxo-2-thioxothiazolidin-3-yl)acetic (2) acid is available commercial (Figure 1) . 2-Amino-5-(3,4,5-trimethoxyphenyl)-1,3,4-thiadiazole (3) was obtained by direct cyclisation of a 3,4,5-trimethoxy benzoic acid and thiosemicarbazide in the presence of phosphorus oxychloride, the latter refluxed with substituted α-haloaryl ketones in dry ethanol yielded the imidazothiadiazoles (4a-g) in good yield. It is well established that this reaction proceeds via the intermediate iminothiadiazole [9] , which undergoes The formation of 2-aminothiadiazole (3) by the reaction between 3,4,5-trimethoxy benzoic acid and thiosemicarbazide was confirmed by IR spectra, which showed the presence of amine (-NH2) band and absence of carbonyl stretching of carboxylic acid. Structures of imidazothiadiazole derivatives (4a-g) were established by the absence of amine (-NH2) band in IR spectra and appearance of imidazole proton (H-5) around  8.6 in the 1 H NMR spectra. IR spectra of aldehydes (5a-g) displayed a sharp band for carbonyl stretching frequency (vC=O) around 1680 cm -1 and the signal for imidazole proton (H-5) in 1 H NMR spectrum was absent. A new signal for aldehyde proton was observed around : 10.00 ppm in the 1 H NMR spectra, thus substantiating the formation of imidazo [2,1-b] [1, 3, 4] thiadiazole-5-carbaldehydes. The absence of aldehyde protons and presence of the methylidene proton around  7.7 in 1 H NMR spectra of the product supported the formation of title compounds (6a-g) and (7a-g).
Antimicrobial activity
The fourteen synthesized compounds were screened for their antibacterial and antifungal screening using twofold serial dilution technique [32] . , compounds 6a,  6b, 6c, 6d, 6g, 7a,7b, 7c,7d and 7g showed weak to moderate activity.
The antifungal screening of all compounds was carried against four fungal strains, Candida albicans (ATCC 2091), Aspergillus flavus (NCIM No. 524), Aspergillus niger (ATCC 6275), and Cryptococcus neoformans (clinical isolate). All synthesized compounds showed significant antifungal activity against different fungal strains. Although compounds 7e and 7f showed good antifungal activity against all the fungal strains, compounds 6e and 6f also showed remarkable activity against all the fungal strains. All other compounds showed moderate activity against all the fungal strains but compounds 6a, 6b, 6d showed weak activity against A. niger and 6b against A. flavus.
A total analysis of the antibacterial and antifungal activity revealed that (i) the 2-((5Z 
Conclusion
We have synthesized several 2-((5Z 
